Anti Microbial Peptides Market Report 2025

This anti microbial peptides market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The anti microbial peptides market size has grown strongly in recent years. It will grow from $6.49 billion in 2024 to $7.03 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to the rising prevalence of antibiotic-resistant infections, increasing demand for novel antimicrobial therapies, growing concerns over the efficacy of traditional antibiotics, and expansion of research funding for antimicrobial drug discovery.

The anti microbial peptides market size is expected to see strong growth in the next few years. It will grow to $9.63 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to rising demand in healthcare, regulatory approvals, growing investment in peptide-based drug development, rising focus on antimicrobial resistance mitigation, and advancements in peptide synthesis and delivery technologies. Major trends in the forecast period include technological advancements, innovative therapeutics, biotechnology techniques, research and development, development of engineered peptides, and advancements in biotechnology.

The rising incidence of infectious diseases is anticipated to drive the growth of the antimicrobial peptide market. Infectious diseases, caused by harmful organisms such as bacteria, viruses, fungi, or parasites, are increasing due to factors such as climate change, the emergence of drug-resistant pathogens, and poor dietary habits. Antimicrobial peptides present a promising solution for these issues, offering new therapeutic options that address the challenges of antibiotic resistance and the limitations of traditional treatments. For example, in October 2023, the UK public sector information website Gov.uk reported that England saw 3,805 new HIV diagnoses in 2022, a 22% increase from the 3,118 cases in 2021 and a 26% rise from the 3,026 cases in 2020. This surge in infectious diseases is fueling the growth of the antimicrobial peptide market.

Leading companies in the antimicrobial peptide sector are focusing on developing cutting-edge products, such as biodegradable antimicrobial peptides, to tackle antimicrobial resistance and improve treatment effectiveness. Biodegradable antimicrobial peptides are short proteins that decompose into harmless byproducts after neutralizing harmful microorganisms such as bacteria, viruses, and fungi. For instance, in September 2024, Beiersdorf AG, a personal care product manufacturer based in Germany, teamed up with Macro Biologics, a US-based bioengineering firm, to develop these peptides. This partnership aims to create innovative biodegradable antimicrobial solutions, reflecting a trend in the cosmetics industry toward combining advanced biotechnological innovations with sustainability goals.

In December 2023, Invaio Sciences Inc., a US-based biotechnology firm, acquired Peptyde Bio Inc. for an undisclosed sum. This acquisition is intended to bolster Invaio Sciences' capabilities in precision agriculture through advanced peptide-based technologies. Peptyde Bio Inc., also based in the US, specializes in developing novel antimicrobial peptides.

Major companies operating in the anti microbial peptides market are Wuxi AppTec, Sigma Aldrich Chemicals Private Limited, Ipsen S.A., Novozymes A/S, GenScript Biotech, Bachem Holding AG, Basilea Pharmaceutica Ltd., Probiotec Limited, Migenix Inc., Zymeworks Inc., Venatorx Pharmaceuticals Inc., AMPS Biotech Pvt. Ltd., AnaSpec Inc., MediGene AG, Hycult Biotech, Phoenix Biotechnology Inc., Shenzhen Sunsmile Biotechnology Co. Ltd., WatsonBio Sciences, Helix BioMedix, Jiangsu ProteLight Pharmaceutical and Biotechnology Co Ltd.

North America was the largest region in the anti microbial Peptides market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti microbial peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti microbial peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antimicrobial peptides (AMPs) are short proteins that play a vital role in the immune system by defending against bacteria, viruses, fungi, and parasites. They function by disrupting the cell membranes of pathogens, leading to their destruction. AMPs are naturally produced by a wide range of organisms, including humans, animals, and plants, and are being investigated as potential alternatives to traditional antibiotics due to their broad-spectrum antimicrobial activity.

The main types of antimicrobial peptides include plant antimicrobial peptides, bacterial antimicrobial peptides, animal antimicrobial peptides, and insect antimicrobial peptides. Plant antimicrobial peptides are small proteins produced by plants to protect against pathogens such as bacteria, fungi, and viruses. These peptides can address various ailments including pneumonia, hepatitis, bacterial infections, and HIV. They can be administered through different routes, such as topical, subcutaneous, and intravenous. Antimicrobial peptides are distributed through various channels including hospitals, research institutes, specialty clinics, pharmacies, and are used by sectors such as pharmaceuticals and healthcare, agriculture, and biological engineering.

The antimicrobial peptides market research report is one of a series of new reports that provides antimicrobial peptides market statistics, including antimicrobial peptides industry global market size, regional shares, competitors with an antimicrobial peptides market share, detailed antimicrobial peptides market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial peptides industry. This antimicrobial peptides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antimicrobial peptides market consists of sales of natural antimicrobial peptides, synthetic antimicrobial peptides, modified antimicrobial peptides, antimicrobial peptide-based drugs, and antimicrobial peptide-based diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.